Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press15310.17650/1994-4098-2011-0-2-4-9MAMMOLOGY. TOPICAL ISSUEМАММОЛОГИЯ. АКТУАЛЬНАЯ ТЕМАNews on preoperative chemotherapy for breast cancer: according to the proceedings of the 33rd Annual Breast Cancer Symposium (December 8–12, 2010, San-Antonio, USA)Новости предоперационной химиотерапии рака молочной железы: по материалам 33-го ежегодного симпозиума по раку молочной железы (8–12 декабря 2010 г., Сан-Антонио, США)PortnoyS. M.ПортнойС. М.
Russian Federation
sportnoj@yahoo.comN.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, MoscowРОНЦ им. Н.Н. Блохина РАМН, Москва2505201124925072014250720142011https://ojrs.abvpress.ru/ojrs/article/view/153

Effective preoperative systemic therapy is a key stage of treatment for locally advanced breast cancer. The results of recent studies, presented at the symposium, give an insight into new possibilities of chemotherapy. The results that are most interesting and practically useful have been obtained when treating Her-2-positive tumors.

Эффективная предоперационная системная терапия является ключевым этапом лечения местно-распространенного рака молочной железы. Результаты исследований последних лет, продемонстрированные на симпозиуме, дают представление о новых возможностях химиотерапии. Наиболее интересные и полезные с практической точки зрения результаты получены при лечении Her-2-позитивных опухолей.

breast cancerpreoperative systemic therapyрак молочной железыпредоперационная химиотерапия→1. Ramirez-Torres N., Perez-Puentes A., Astudillo-de la Vega H. Effectiveness analysis of neoadjuvant treatment by using 4 FE100С vs 6 FE100С in patients with advanced breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org р1-11-21Ramirez-Torres N., Perez-Puentes A., Astudillo-de la Vega H. Effectiveness analysis of neoadjuvant treatment by using 4 FE100С vs 6 FE100С in patients with advanced breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org р1-11-212. Vriens B.E., Van de Vijver K.K., Boetes C. et al. Sequential versus upfront intensified neoadjuvant chemotherapy in patients with large resectable or locally advanced breast cancer (INTENS), first results from a phase III study of the Dutch breast cancer trialists` group (BOOG). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org р1-11-10Vriens B.E., Van de Vijver K.K., Boetes C. et al. Sequential versus upfront intensified neoadjuvant chemotherapy in patients with large resectable or locally advanced breast cancer (INTENS), first results from a phase III study of the Dutch breast cancer trialists` group (BOOG). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org р1-11-103. Steger G.G., Barrios C., O`Shaughnessy J. et al. Review of capecitabine for the treatment of triple-negative early breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org PD01-03Steger G.G., Barrios C., O`Shaughnessy J. et al. Review of capecitabine for the treatment of triple-negative early breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org PD01-034. Venturini M., Del Mastro L., Aitini E. et al. Open-label phase II study of neoadjuvant bevacizumab combined with FEC→paclitaxel in patients with inflammatory or locally advanced breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-20Venturini M., Del Mastro L., Aitini E. et al. Open-label phase II study of neoadjuvant bevacizumab combined with FEC→paclitaxel in patients with inflammatory or locally advanced breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-205. Carpenter J.T., Forero A., Falkson C.I. et al. Concurrent and sequential bevacizumab and preoperative chemotherapy in the treatment of locally advanced breast cancer — UAB 0493. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-24Carpenter J.T., Forero A., Falkson C.I. et al. Concurrent and sequential bevacizumab and preoperative chemotherapy in the treatment of locally advanced breast cancer — UAB 0493. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-246. Von Minckwitz G., Eidtmann H., Rezai M. et al. Neoadjuvant chemotherapy with or without bevacizumab: primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org S4-6Von Minckwitz G., Eidtmann H., Rezai M. et al. Neoadjuvant chemotherapy with or without bevacizumab: primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org S4-67. Untch M., Loibl S., Bischoff J. et al. Lapatinib vs trastuzumab in combination with neoadjuvant antracycline-taxane-based chemotherapy: primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org S3-1Untch M., Loibl S., Bischoff J. et al. Lapatinib vs trastuzumab in combination with neoadjuvant antracycline-taxane-based chemotherapy: primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org S3-18. Baselga J., Bradbury I., Eidtmann H. et al. First results of the NeoALTTO trial (BIG 01- 06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with Her-2-positive primary breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org S3-3Baselga J., Bradbury I., Eidtmann H. et al. First results of the NeoALTTO trial (BIG 01- 06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with Her-2-positive primary breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org S3-39. Gianni L., Pienkowski T., Im Y.-H. et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (NeoSphere). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org S3-2Gianni L., Pienkowski T., Im Y.-H. et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (NeoSphere). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org S3-210. Al-Tweigeri T.A., Alsayed A.A., Ibrahim M.M. et al. A multicenter prospective phase II trial of neo-adjuvant (FEC100)/cisplatin- docetaxel with or without trastuzumab in locally advanced breast cancer. Gulf oncology research group (GORG-001). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-08Al-Tweigeri T.A., Alsayed A.A., Ibrahim M.M. et al. A multicenter prospective phase II trial of neo-adjuvant (FEC100)/cisplatin- docetaxel with or without trastuzumab in locally advanced breast cancer. Gulf oncology research group (GORG-001). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-0811. Untch M., Fasching P.A., Konacny G.E. et al. Pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy. Three year median follow-up data of the TECHNO trial. Cancer Res 2010;70(24 Suppl 2). www. sabcs.org P1-11-03Untch M., Fasching P.A., Konacny G.E. et al. Pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy. Three year median follow-up data of the TECHNO trial. Cancer Res 2010;70(24 Suppl 2). www. sabcs.org P1-11-0312. Coussy F., Cuvier C., Hamy A.S. et al. Neoadjuvant chemotherapy in lobular and ductal carcinoma: comparison of clinical, pathological response rates and survival. Cancer Res 2010;70(24 Suppl 2). www.sabcs. org р1-11-14Coussy F., Cuvier C., Hamy A.S. et al. Neoadjuvant chemotherapy in lobular and ductal carcinoma: comparison of clinical, pathological response rates and survival. Cancer Res 2010;70(24 Suppl 2). www.sabcs. org р1-11-1413. Giacchetti S., Porcher R., Lehmann-Che J. et al. Comparison of long term outcome of locally advanced and inflammatory breast cancers treated with dose dense neoadjuvant chemotherapy. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-17-03Giacchetti S., Porcher R., Lehmann-Che J. et al. Comparison of long term outcome of locally advanced and inflammatory breast cancers treated with dose dense neoadjuvant chemotherapy. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-17-0314. Sanchez-Rovira P., de la Haba J., Fernandez M. et al. Predictive response factors (PRF) in an open, non-randomized, phase II study of a combination of bevacizumab (BZ) and sequential chemotherapy as preoperative treatment in patients with operable Her-2-negative breast cancer (BC). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-09Sanchez-Rovira P., de la Haba J., Fernandez M. et al. Predictive response factors (PRF) in an open, non-randomized, phase II study of a combination of bevacizumab (BZ) and sequential chemotherapy as preoperative treatment in patients with operable Her-2-negative breast cancer (BC). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-0915. Saura C., Tseng L.-M., Chan S. et al. Phase 2 study of ixabepilone versus paclitaxel as neoadjuvant therapy for early stage breast cancer with comparative biomarker analysis. Cancer Res 2010;70(24 Suppl 2). www.sabcs. org PD07-01Saura C., Tseng L.-M., Chan S. et al. Phase 2 study of ixabepilone versus paclitaxel as neoadjuvant therapy for early stage breast cancer with comparative biomarker analysis. Cancer Res 2010;70(24 Suppl 2). www.sabcs. org PD07-0116. Sato T., Hayashida T., Takahashi M. et al. Paclitaxel without antracycline in Her-2- positive operable breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-04Sato T., Hayashida T., Takahashi M. et al. Paclitaxel without antracycline in Her-2- positive operable breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-0417. Guitu S., Arnould L., Gauthier M., et al. Pathologic response and survival after neoadjuvant therapy for breast cancer: a 30-year sigle-center study. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org Р1-11-02Guitu S., Arnould L., Gauthier M., et al. Pathologic response and survival after neoadjuvant therapy for breast cancer: a 30-year sigle-center study. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org Р1-11-0218. Tokudome N., Ito Y., Takahashi S. et al. Triple negative or Her-2-positive subtypes of breast cancer groups are chemo-sensitive, but higher rate of brain metastasis contributes poorer prognosis. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-13Tokudome N., Ito Y., Takahashi S. et al. Triple negative or Her-2-positive subtypes of breast cancer groups are chemo-sensitive, but higher rate of brain metastasis contributes poorer prognosis. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-1319. Li S.P., Burcombe R., Beresford M.J. et al. Predicting outcome with Ki-67 in primary breast cancer in the neoadjuvant setting. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org PD07-04Li S.P., Burcombe R., Beresford M.J. et al. Predicting outcome with Ki-67 in primary breast cancer in the neoadjuvant setting. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org PD07-0420. Tanei T., Shimomura A., Shimazu K. et al. Prognostic significance of Ki-67 index after neoadjuvant chemotherapy for human breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org Р1-11-19Tanei T., Shimomura A., Shimazu K. et al. Prognostic significance of Ki-67 index after neoadjuvant chemotherapy for human breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org Р1-11-1921. Wada N., Asaga S., Yamauchi C. et al. Breast cancer patients with neoadjuvant chemotherapy have a different clinical significance of the Ki-67 expression before and after the treatment. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P3-10-28Wada N., Asaga S., Yamauchi C. et al. Breast cancer patients with neoadjuvant chemotherapy have a different clinical significance of the Ki-67 expression before and after the treatment. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P3-10-28